|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 901.2 USD | +0.79% |
|
-3.74% | +2.61% |
| Apr. 17 | UBS Adjusts Regeneron Pharmaceuticals Price Target to $1,099 From $1,090, Maintains Buy Rating | MT |
| Apr. 17 | The market is pinning its hopes on earnings reports |  |
Jan 12 (Reuters) - The U.S. government will buy 1.25 million additional doses of Regeneron Pharmaceuticals Inc's COVID-19 antibody cocktail to be used in non-hospitalized COVID-19 patients, the drugmaker said on Tuesday.
The new agreement brings the total potential U.S. supply to over 1.5 million doses, according to Regeneron. (Reporting by Trisha Roy in Bengaluru; Editing by Shounak Dasgupta)
| 1st Jan change | Capi. | |
|---|---|---|
| +2.61% | 96.84B | |
| -3.39% | 102B | |
| -1.14% | 21.48B | |
| -18.14% | 20.82B | |
| -7.45% | 18.6B | |
| -40.70% | 16.81B | |
| -26.89% | 13.78B | |
| +1.12% | 13.4B | |
| +22.25% | 11.06B | |
| -18.85% | 8.88B |
REGENERON PHARMACEUTICALS, INC. 
